Thyrocare Technologies Ltd (THYROCARE) Q4FY25 Concall Summary - Mar-2025 Qtr
Performance Overview
- Thyrocare achieved NABL accreditation across all its labs, becoming the first and only fully accredited national laboratory chain in India.
- The company processed 167.9 million tests in FY25, a 14% year-on-year increase, exceeding the combined volume of its competitors.
- It served 16.7 million patients, marking an 11% year-on-year growth.
- Strategic acquisitions of Polo Labs and Vimta Labs expanded Thyrocare's footprint in North and South India, respectively.
- The partnerships business thrived, driven by new health tech clients and the acquisition of Think Health, which added ECG at-home services.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.